SynB1-ELP

SynB1-ELP is a thermally responsive macromolecular carrier platform designed for the targeted delivery of therapeutic agents, particularly in oncology. It is a fusion polypeptide comprising two functional domains: SynB1, a cell-penetrating peptide (CPP) derived from protegrin-1 that promotes cellular uptake, and an elastin-like polypeptide (ELP), which exhibits an inverse phase transition temperature. This property causes the carrier to aggregate and accumulate in tissues subjected to local hyperthermia (typically 40-42°C), such as a heated tumor mass. SynB1-ELP is primarily utilized as a delivery vehicle for potent cytotoxic payloads, most notably the doxorubicin derivative N-butyldiacetate doxorubicin (NBD), forming the conjugate SynB1-ELP-NBD. This approach aims to increase the local concentration of the drug at the tumor site while minimizing systemic exposure and associated toxicities. Preclinical studies in pancreatic cancer models have shown that the SynB1-ELP-NBD conjugate is significantly more potent than free doxorubicin and allows for a higher maximum tolerated dose.